Clinical trial
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
NCT02582671 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
- Lead sponsor
- AbbVie
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 5, 2015
- Completion date
- November 29, 2017
- Enrollment
- 101 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis c